Preclinical Data from VBI-1901, VBI’s Therapeutic Cancer Vaccine Candidate
October 25, 2016 | Video
In preclinical studies, VBI demonstrated that its vaccine candidate stimulated immune responses critical to efficacious anti-tumor immunity.
October 25, 2016 | Video
In preclinical studies, VBI demonstrated that its vaccine candidate stimulated immune responses critical to efficacious anti-tumor immunity.
Discussion of Data Presented at Society for Neuro-Oncology (SNO) 2020 Annual Meeting
Date: November 19, 2020
Presenters: Jeff Baxter, VBI CEO, and Dr. David E. Anderson, Ph.D., VBI CSO
Discussion of Data Presented at 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting II
Date: June 22, 2020
Presenters: Dr. Allen Waziri, M.D., and Dr. David E. Anderson, VBI CSO
Date: October 27, 2016
Presenters: Dr. Daniel Shouval, M.D., and Dr. Florian Schödel, M.D.
Date: October 26, 2016
Presenters: Dr. David E. Anderson, VBI CSO
Date: October 25, 2016
Presenters: Jeff Baxter, VBI CEO
Date: October 25, 2016
Presenters: Dr. David E. Anderson, VBI CSO
Date: October 15, 2016
Presenters: Dr. Daniel Shouval, M.D., and Dr. Florian Schödel, M.D.
Date: August 15, 2014
Presenters: Dr. David E. Anderson, VBI CSO
Date: August 5, 2014
Presenters: Dr. David E. Anderson, VBI CSO
